Advances in Treating PNH (Paroxysmal Nocturnal Hemoglobinuria) with Dr. Allyson Pishko - 2022
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
Key Points
Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD.
Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids.
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.
Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team.
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated
PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”